Key result
An additional nirsevimab dose could avert RSV hospitalizations for infants born out of season.
Why the study?
The optimal RSV immunisation strategy for infants born in the RSV off-season remains unclear.
Does an additional nirsevimab dose reduce RSV hospitalisations in infants born in the RSV off-season?
Observational
Does an additional nirsevimab dose reduce RSV hospitalisations in infants born in the RSV off-season?
An additional nirsevimab dose for infants born in the RSV off-season may significantly reduce RSV hospitalisations and healthcare costs.
Answers are grounded in this paper and cite their sources.
May support evaluating an extra nirsevimab dose for off-season births; leaves open prospective trials to confirm benefit.
We explored age-specific infant RSV laboratory-confirmed hospitalisation rates by birth month in Western Australia. Population-based analyses were supplemented with a Susceptible-Exposed-Infected-Recovered-(Susceptible) mathematical model simulations. RSV-hospitalisations peaked for infants aged 1-3 months born in-season and 6-10 months born out-of-season, that is spring and summer born infants. Offering an additional nirsevimab dose to spring and summer born infants could avert significant hospitalisations and healthcare costs.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2026) conducted an observational in RSV infection. Additional nirsevimab dose was evaluated on RSV laboratory-confirmed hospitalisation. RSV hospitalisations peaked at 1-3 months for infants born in-season and 6-10 months for those born out-of-season, suggesting an additional nirsevimab dose could avert hospitalisations.
Synapse has enriched 10 related papers. Consider them for comparative context: